

Strides Vivimed JV receives approval for Albendazole Tablets

12 December 2018 | News

This is the second generic approval by US FDA for Albendazole Tablets.



Strides Pharma Science Limited (Strides) has announced that its 50:50 JV Strides Vivimed Pte. Ltd, Singapore has received approval for Albendazole Tablets USP 200 mg from the United States Food & Drug Administration (US FDA).

This is the second generic approval by US FDA for Albendazole Tablets.

Albendazole Tablets is a generic version of Albenza Tablets of Amneal Pharmaceuticals, Inc.

According to IQVIA MAT data, the US market for Albendazole Tablets USP 200 mg is approximately US\$ 100 Million.

Albendazole is an anthelmintic medication used to treat certain infections caused by tapeworm. Albendazole prevents newly hatched insect larvae (worms) from growing or multiplying in the body.